Engineered immune cells target deadly childhood brain tumors in first human trial

NCT ID NCT07087002

First seen Oct 31, 2025 · Last updated Apr 24, 2026 · Updated 26 times

Summary

This early-stage trial tests a new treatment for children and young adults with medulloblastoma or similar brain tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack a protein called GPC2 found on tumor cells. These cells are delivered directly into the fluid around the brain. The main goals are to see if the cells can be made safely and to find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MEDULLOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lucile Packard Children's Hospital Stanford

    RECRUITING

    Palo Alto, California, 94304, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.